25 XP   0   0   10

Denali Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Denali Therapeutics Inc together

PenkeI guess you are interested in Denali Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Denali Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Denali Therapeutics Inc

I send you an email if I find something interesting about Denali Therapeutics Inc.

Quick analysis of Denali Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Denali Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$7.41
Expected worth in 1 year
$7.33
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
$-0.08
Return On Investment
-0.4%

For what price can you sell your share?

Current Price per Share
$20.52
Expected price per share
$16.11 - $21.87
How sure are you?
50%

1. Valuation of Denali Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$20.52

Intrinsic Value Per Share

$-220.70 - $-265.03

Total Value Per Share

$-213.29 - $-257.62

2. Growth of Denali Therapeutics Inc (5 min.)




Is Denali Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$914m$161.6m15.0%

How much money is Denali Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$36.3m-$81.1m$44.8m123.6%
Net Profit Margin-2,022.9%-1,031.5%--

How much money comes from the company's main activities?

3. Financial Health of Denali Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#57 / 1031

Most Revenue
#89 / 1031

Most Profit
#873 / 1031

Most Efficient
#869 / 1031

What can you expect buying and holding a share of Denali Therapeutics Inc? (5 min.)

Welcome investor! Denali Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Denali Therapeutics Inc.

What can you expect buying and holding a share of Denali Therapeutics Inc?

First you should know what it really means to hold a share of Denali Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Denali Therapeutics Inc is $20.52. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Denali Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Denali Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.41. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Denali Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.86-4.2%-0.27-1.3%-0.59-2.9%-0.32-1.6%-0.27-1.3%
Usd Book Value Change Per Share-0.63-3.1%-0.02-0.1%0.140.7%0.170.8%0.251.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.63-3.1%-0.02-0.1%0.140.7%0.170.8%0.251.2%
Usd Price Per Share21.46-23.66-30.03-34.17-25.88-
Price to Earnings Ratio-6.25--3.78--13.68--13.75--11.13-
Price-to-Total Gains Ratio-34.18--27.52--66.22--71.05--59.58-
Price to Book Ratio2.90-3.07-4.62-5.59-4.59-
Price-to-Total Gains Ratio-34.18--27.52--66.22--71.05--59.58-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share20.52
Number of shares48
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.17
Usd Total Gains Per Share-0.020.17
Gains per Quarter (48 shares)-0.998.35
Gains per Year (48 shares)-3.9633.40
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4-1403323
20-8-1806756
30-12-22010089
40-16-260134122
50-20-300167155
60-24-340200188
70-28-380234221
80-32-420267254
90-36-460301287
100-40-500334320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%2.018.00.010.0%4.026.00.013.3%4.026.00.013.3%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%10.019.01.033.3%10.019.01.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.030.00.0%0.00.030.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%10.019.01.033.3%10.019.01.033.3%

Fundamentals of Denali Therapeutics Inc

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-03-20 15:26:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Denali Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Denali Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Denali Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,022.9%+2,022.9%
TTM-2,022.9%YOY-1,031.5%-991.4%
TTM-2,022.9%5Y-1,125.2%-897.7%
5Y-1,125.2%10Y-1,081.1%-44.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM-2,022.9%-202.3%-1,820.6%
YOY-1,031.5%-263.0%-768.5%
5Y-1,125.2%-452.4%-672.8%
10Y-1,081.1%-589.0%-492.1%
1.1.2. Return on Assets

Shows how efficient Denali Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • -10.4% Return on Assets means that Denali Therapeutics Inc generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Denali Therapeutics Inc:

  • The MRQ is -10.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.4%TTM-3.0%-7.3%
TTM-3.0%YOY-6.1%+3.1%
TTM-3.0%5Y-4.8%+1.8%
5Y-4.8%10Y-6.4%+1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.4%-12.5%+2.1%
TTM-3.0%-12.2%+9.2%
YOY-6.1%-11.2%+5.1%
5Y-4.8%-13.3%+8.5%
10Y-6.4%-14.6%+8.2%
1.1.3. Return on Equity

Shows how efficient Denali Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • -11.6% Return on Equity means Denali Therapeutics Inc generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Denali Therapeutics Inc:

  • The MRQ is -11.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.6%TTM-4.1%-7.5%
TTM-4.1%YOY-9.0%+4.9%
TTM-4.1%5Y-6.6%+2.5%
5Y-6.6%10Y-7.2%+0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.6%-16.0%+4.4%
TTM-4.1%-15.8%+11.7%
YOY-9.0%-13.9%+4.9%
5Y-6.6%-18.2%+11.6%
10Y-7.2%-19.1%+11.9%

1.2. Operating Efficiency of Denali Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Denali Therapeutics Inc is operating .

  • Measures how much profit Denali Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Denali Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,324.2%+2,324.2%
TTM-2,324.2%YOY-1,079.8%-1,244.3%
TTM-2,324.2%5Y-1,224.7%-1,099.4%
5Y-1,224.7%10Y-1,171.0%-53.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-2,324.2%-208.5%-2,115.7%
YOY-1,079.8%-280.2%-799.6%
5Y-1,224.7%-459.9%-764.8%
10Y-1,171.0%-596.9%-574.1%
1.2.2. Operating Ratio

Measures how efficient Denali Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM24.422-24.422
TTM24.422YOY11.967+12.455
TTM24.4225Y15.081+9.341
5Y15.08110Y16.703-1.622
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM24.4223.181+21.241
YOY11.9673.609+8.358
5Y15.0815.554+9.527
10Y16.7037.396+9.307

1.3. Liquidity of Denali Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Denali Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.65 means the company has $13.65 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 13.646. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.685. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.646TTM12.685+0.961
TTM12.685YOY3.256+9.428
TTM12.6855Y11.626+1.059
5Y11.62610Y13.521-1.895
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.6463.987+9.659
TTM12.6854.440+8.245
YOY3.2565.569-2.313
5Y11.6266.158+5.468
10Y13.5216.492+7.029
1.3.2. Quick Ratio

Measures if Denali Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 24.94 means the company can pay off $24.94 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 24.937. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 23.235. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ24.937TTM23.235+1.702
TTM23.235YOY5.890+17.344
TTM23.2355Y19.947+3.288
5Y19.94710Y21.609-1.662
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ24.9373.653+21.284
TTM23.2354.158+19.077
YOY5.8905.515+0.375
5Y19.9476.012+13.935
10Y21.6096.206+15.403

1.4. Solvency of Denali Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Denali Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Denali Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Denali Therapeutics Inc assets are financed with 10.7% credit (debt) and the remaining percentage (100% - 10.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 0.107. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.152. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.107TTM0.152-0.045
TTM0.152YOY0.311-0.160
TTM0.1525Y0.250-0.098
5Y0.25010Y0.201+0.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1070.336-0.229
TTM0.1520.330-0.178
YOY0.3110.267+0.044
5Y0.2500.367-0.117
10Y0.2010.378-0.177
1.4.2. Debt to Equity Ratio

Measures if Denali Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.9% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 0.119. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.196. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.119TTM0.196-0.077
TTM0.196YOY0.454-0.258
TTM0.1965Y0.345-0.149
5Y0.34510Y0.264+0.081
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1190.376-0.257
TTM0.1960.398-0.202
YOY0.4540.334+0.120
5Y0.3450.431-0.086
10Y0.2640.476-0.212

2. Market Valuation of Denali Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Denali Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -6.25 means the investor is paying $-6.25 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Denali Therapeutics Inc:

  • The EOD is -5.975. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.249. Based on the earnings, the company is expensive. -2
  • The TTM is -3.776. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.975MRQ-6.249+0.274
MRQ-6.249TTM-3.776-2.473
TTM-3.776YOY-13.679+9.903
TTM-3.7765Y-13.745+9.969
5Y-13.74510Y-11.128-2.617
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.975-2.697-3.278
MRQ-6.249-2.422-3.827
TTM-3.776-2.709-1.067
YOY-13.679-4.116-9.563
5Y-13.745-6.257-7.488
10Y-11.128-6.478-4.650
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Denali Therapeutics Inc:

  • The EOD is -7.076. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.400. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.294. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.076MRQ-7.400+0.324
MRQ-7.400TTM-9.294+1.894
TTM-9.294YOY-16.615+7.321
TTM-9.2945Y-117.775+108.481
5Y-117.77510Y-79.623-38.152
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.076-3.344-3.732
MRQ-7.400-2.939-4.461
TTM-9.294-3.486-5.808
YOY-16.615-5.592-11.023
5Y-117.775-8.464-109.311
10Y-79.623-8.872-70.751
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Denali Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.90 means the investor is paying $2.90 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Denali Therapeutics Inc:

  • The EOD is 2.770. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.897. Based on the equity, the company is underpriced. +1
  • The TTM is 3.071. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.770MRQ2.897-0.127
MRQ2.897TTM3.071-0.174
TTM3.071YOY4.621-1.550
TTM3.0715Y5.590-2.519
5Y5.59010Y4.590+1.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.7702.198+0.572
MRQ2.8972.042+0.855
TTM3.0712.121+0.950
YOY4.6212.907+1.714
5Y5.5903.682+1.908
10Y4.5904.114+0.476
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Denali Therapeutics Inc.

3.1. Institutions holding Denali Therapeutics Inc

Institutions are holding 79.479% of the shares of Denali Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baillie Gifford & Co Limited.10.24770.242514260724-420303-2.8629
2023-12-31BlackRock Inc8.29510.0063115434466581506.0462
2023-12-31Vanguard Group Inc7.78560.0051108344832367022.2335
2023-12-31Wellington Management Company LLP5.22760.02917274717-14243-0.1954
2023-12-31Temasek Holdings Ltd.4.95540.8283689599200
2023-12-31Crestline Management LP4.067810.35095660732-300000-5.0329
2023-12-31State Street Corporation3.94220.00575485948121062028.3164
2023-12-31Capital Research Global Investors2.09080.01542909528292051.0139
2023-12-31Geode Capital Management, LLC1.9110.00626592961274615.0343
2023-09-30Flagship Ventures Management, Inc.1.88273.9233261996800
2023-12-31Baker Bros Advisors LP1.87350.6366260719631519313.7519
2023-12-31T. Rowe Price Associates, Inc.1.84990.00742574321-317629-10.9832
2023-12-31Bank of New York Mellon Corp1.34420.00811870627-93061-4.7391
2023-12-31Marshall Wace Asset Management Ltd1.19820.0606166739716673970
2023-12-31Credit Suisse First Boston (CSFB)1.13270.0326157622189120.5686
2023-12-31Federated Hermes Inc0.97150.072135190000
2023-12-31Casdin Capital, LLC0.93422.7385130000000
2023-12-31Gilder Gagnon Howe & CO LLC0.87630.35911219392-26807-2.1511
2023-12-31NORGES BANK0.82830.0043115264612844012.5404
2023-12-31Yiheng Capital LLC0.82691.4235115068400
Total 62.241620.755386615218+3210037+3.7%

3.2. Funds holding Denali Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Scottish Mortgage Ord4.68840.6196524392-2059-0.0315
2023-12-31Vanguard Health Care Inv3.66520.2358510045400
2024-01-31Baillie Gifford US Equity Growth2.52290.7316351087700
2023-12-31Vanguard US Growth Investor2.52290.18833510877-143973-3.9392
2024-02-29Vanguard Total Stock Mkt Idx Inv2.3370.00423252243-13287-0.4069
2024-02-29SPDR® S&P Biotech ETF2.17450.75593026066565201.9033
2024-02-29iShares Russell 2000 ETF2.08460.0922900978-474-0.0163
2024-02-29Vanguard Small Cap Index1.91950.03762671180243530.9201
2023-12-31American Funds SMALLCAP World A1.80570.07492512759292051.1759
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.31520.0355183024313040.0713
2024-01-31Baillie Gifford American B Inc1.20220.71411673002-35541-2.0802
2024-02-29Vanguard Small Cap Growth Index Inv1.07750.0851499506249131.6895
2024-01-31CS (Lux) Digital Health Equity SB USD1.0061.4836140000000
2023-12-31US Small-Cap Growth II Equity Comp0.86080.10351197891-3830-0.3187
2023-12-31T. Rowe Price New Horizons0.86080.10391197891-3830-0.3187
2023-12-31Fidelity Small Cap Index0.84480.09931175612148971.2834
2024-02-29iShares Russell 2000 Growth ETF0.74570.18081037711-1207-0.1162
2023-12-31Federated Hermes Kaufmann Small Cap A0.67550.479794000000
2023-12-31Federated Hermes Kaufmann Small Cap Grow0.67550.479794000000
2024-02-29iShares Biotechnology ETF0.62730.227872979-3930-0.4482
Total 33.6126.731446774661-56939-0.1%

3.3. Insider Transactions

Insiders are holding 13.852% of the shares of Denali Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-15Vicki L SatoSELL166618.37
2024-02-13Carole HoSELL278417.29
2024-02-13Ryan J WattsSELL958917.29
2024-02-13Steve E KrognesSELL275017.29
2024-01-16Vicki L SatoSELL166618.42
2024-01-10Carole HoSELL466819.02
2024-01-09Ryan J WattsSELL781819.78
2024-01-05Steve E KrognesSELL320819.43
2024-01-05Ryan J WattsSELL1748319.43
2024-01-05Carole HoSELL997219.43
2023-12-15Vicki L SatoSELL166623.39
2023-11-15Vicki L SatoSELL166619.13
2023-10-16Vicki L SatoSELL166620.66
2023-09-15Vicki L SatoSELL166623.62
2023-08-23Carole HoSELL252223.22
2023-08-21Carole HoSELL247822.6
2023-08-21Steve E KrognesSELL141922.6
2023-08-21Steve E KrognesSELL141922.6
2023-08-21Ryan J WattsSELL230922.59
2023-08-21Ryan J WattsSELL230922.59

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Denali Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.628-0.021-97%0.144-536%0.174-461%0.247-354%
Book Value Per Share--7.4087.703-4%6.568+13%6.109+21%4.889+52%
Current Ratio--13.64612.685+8%3.256+319%11.626+17%13.521+1%
Debt To Asset Ratio--0.1070.152-30%0.311-66%0.250-57%0.201-47%
Debt To Equity Ratio--0.1190.196-39%0.454-74%0.345-65%0.264-55%
Dividend Per Share----0%-0%-0%-0%
Eps---0.859-0.265-69%-0.586-32%-0.320-63%-0.268-69%
Free Cash Flow Per Share---0.725-0.664-8%-0.472-35%-0.219-70%-0.163-78%
Free Cash Flow To Equity Per Share---0.691-0.632-9%0.086-900%0.137-606%0.180-484%
Gross Profit Margin--1.0181.005+1%1.000+2%1.001+2%1.001+2%
Intrinsic Value_10Y_max---265.031--------
Intrinsic Value_10Y_min---220.703--------
Intrinsic Value_1Y_max---5.597--------
Intrinsic Value_1Y_min---5.486--------
Intrinsic Value_3Y_max---32.792--------
Intrinsic Value_3Y_min---30.983--------
Intrinsic Value_5Y_max---79.246--------
Intrinsic Value_5Y_min---72.179--------
Market Cap2855563200.000-5%2986373600.0003305588385.938-10%4178279000.000-29%4757222697.188-37%3602785024.792-17%
Net Profit Margin----20.2290%-10.3150%-11.2520%-10.8110%
Operating Margin----23.2420%-10.7980%-12.2470%-11.7100%
Operating Ratio---24.422-100%11.967-100%15.081-100%16.703-100%
Pb Ratio2.770-5%2.8973.071-6%4.621-37%5.590-48%4.590-37%
Pe Ratio-5.975+4%-6.249-3.776-40%-13.679+119%-13.745+120%-11.128+78%
Price Per Share20.520-5%21.46023.660-9%30.025-29%34.167-37%25.877-17%
Price To Free Cash Flow Ratio-7.076+4%-7.400-9.294+26%-16.615+125%-117.775+1492%-79.623+976%
Price To Total Gains Ratio-32.681+4%-34.178-27.521-19%-66.221+94%-71.052+108%-59.583+74%
Quick Ratio--24.93723.235+7%5.890+323%19.947+25%21.609+15%
Return On Assets---0.104-0.030-71%-0.061-41%-0.048-54%-0.064-38%
Return On Equity---0.116-0.041-65%-0.090-23%-0.066-43%-0.072-38%
Total Gains Per Share---0.628-0.021-97%0.144-536%0.174-461%0.247-354%
Usd Book Value--1030954000.0001075704000.000-4%914027000.000+13%850850850.000+21%680903833.333+51%
Usd Book Value Change Per Share---0.628-0.021-97%0.144-536%0.174-461%0.247-354%
Usd Book Value Per Share--7.4087.703-4%6.568+13%6.109+21%4.889+52%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.859-0.265-69%-0.586-32%-0.320-63%-0.268-69%
Usd Free Cash Flow---100892000.000-92732500.000-8%-65637250.000-35%-30490300.000-70%-22712866.667-77%
Usd Free Cash Flow Per Share---0.725-0.664-8%-0.472-35%-0.219-70%-0.163-78%
Usd Free Cash Flow To Equity Per Share---0.691-0.632-9%0.086-900%0.137-606%0.180-484%
Usd Market Cap2855563200.000-5%2986373600.0003305588385.938-10%4178279000.000-29%4757222697.188-37%3602785024.792-17%
Usd Price Per Share20.520-5%21.46023.660-9%30.025-29%34.167-37%25.877-17%
Usd Profit---119473000.000-36306000.000-70%-81178250.000-32%-44349800.000-63%-34918766.667-71%
Usd Revenue---82632750.000-100%27115750.000-100%42499600.000-100%37476700.000-100%
Usd Total Gains Per Share---0.628-0.021-97%0.144-536%0.174-461%0.247-354%
 EOD+3 -5MRQTTM+9 -23YOY+12 -205Y+12 -2010Y+12 -20

4.2. Fundamental Score

Let's check the fundamental score of Denali Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.975
Price to Book Ratio (EOD)Between0-12.770
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than124.937
Current Ratio (MRQ)Greater than113.646
Debt to Asset Ratio (MRQ)Less than10.107
Debt to Equity Ratio (MRQ)Less than10.119
Return on Equity (MRQ)Greater than0.15-0.116
Return on Assets (MRQ)Greater than0.05-0.104
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Denali Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.631
Ma 20Greater thanMa 5020.539
Ma 50Greater thanMa 10018.669
Ma 100Greater thanMa 20019.163
OpenGreater thanClose20.860
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -6,8864,369-2,5171,076-1,441790-6511,294643



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,153,917
Total Liabilities122,963
Total Stockholder Equity1,030,954
 As reported
Total Liabilities 122,963
Total Stockholder Equity+ 1,030,954
Total Assets = 1,153,917

Assets

Total Assets1,153,917
Total Current Assets1,064,137
Long-term Assets89,780
Total Current Assets
Cash And Cash Equivalents 127,106
Short-term Investments 907,405
Net Receivables 2,700
Other Current Assets 26,926
Total Current Assets  (as reported)1,064,137
Total Current Assets  (calculated)1,064,137
+/-0
Long-term Assets
Property Plant Equipment 71,637
Long-term Assets Other 16,543
Long-term Assets  (as reported)89,780
Long-term Assets  (calculated)88,180
+/- 1,600

Liabilities & Shareholders' Equity

Total Current Liabilities77,982
Long-term Liabilities44,981
Total Stockholder Equity1,030,954
Total Current Liabilities
Short-term Debt 7,260
Accounts payable 9,483
Other Current Liabilities 61,239
Total Current Liabilities  (as reported)77,982
Total Current Liabilities  (calculated)77,982
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt44,981
Long-term Liabilities  (as reported)44,981
Long-term Liabilities  (calculated)44,981
+/- 0
Total Stockholder Equity
Common Stock1,711
Retained Earnings -1,116,211
Accumulated Other Comprehensive Income 643
Other Stockholders Equity 2,144,811
Total Stockholder Equity (as reported)1,030,954
Total Stockholder Equity (calculated)1,030,954
+/-0
Other
Capital Stock1,711
Cash and Short Term Investments 1,034,511
Common Stock Shares Outstanding 138,245
Liabilities and Stockholders Equity 1,153,917
Net Debt -74,865
Net Invested Capital 1,030,954
Net Working Capital 986,155
Property Plant and Equipment Gross 117,640
Short Long Term Debt Total 52,241



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312015-12-31
> Total Assets 
36,683
271,067
231,379
231,379
210,309
486,721
613,953
572,055
544,475
661,984
676,596
637,604
602,978
553,231
695,865
647,337
1,070,306
1,604,280
1,547,858
1,509,815
1,449,966
1,404,162
1,320,858
1,292,462
1,227,606
1,460,242
1,409,344
1,305,734
1,236,777
1,153,917
1,153,9171,236,7771,305,7341,409,3441,460,2421,227,6061,292,4621,320,8581,404,1621,449,9661,509,8151,547,8581,604,2801,070,306647,337695,865553,231602,978637,604676,596661,984544,475572,055613,953486,721210,309231,379231,379271,06736,683
   > Total Current Assets 
33,431
181,955
189,317
189,317
188,243
409,607
377,422
377,418
383,403
480,836
499,533
495,981
494,377
430,031
604,785
559,409
970,866
1,495,655
1,431,622
1,341,745
1,055,509
897,234
988,436
1,114,600
1,138,526
1,372,319
1,325,162
1,224,062
1,142,884
1,064,137
1,064,1371,142,8841,224,0621,325,1621,372,3191,138,5261,114,600988,436897,2341,055,5091,341,7451,431,6221,495,655970,866559,409604,785430,031494,377495,981499,533480,836383,403377,418377,422409,607188,243189,317189,317181,95533,431
       Cash And Cash Equivalents 
30,740
39,853
41,307
41,307
36,269
218,375
44,001
33,088
43,651
77,123
39,661
62,936
82,673
79,449
207,537
137,184
351,047
507,144
435,321
485,680
394,553
293,477
104,953
155,088
118,615
218,044
68,131
131,973
148,011
127,106
127,106148,011131,97368,131218,044118,615155,088104,953293,477394,553485,680435,321507,144351,047137,184207,53779,44982,67362,93639,66177,12343,65133,08844,001218,37536,26941,30741,30739,85330,740
       Short-term Investments 
0
138,478
145,657
145,657
149,532
187,851
329,401
339,503
331,307
387,174
445,820
415,667
396,717
335,907
379,713
412,397
610,154
962,553
977,827
823,251
644,622
571,930
852,569
913,580
987,440
1,118,171
1,220,322
1,059,014
961,245
907,405
907,405961,2451,059,0141,220,3221,118,171987,440913,580852,569571,930644,622823,251977,827962,553610,154412,397379,713335,907396,717415,667445,820387,174331,307339,503329,401187,851149,532145,657145,657138,4780
       Net Receivables 
0
438
0
0
0
464
0
464
0
8,546
8,546
0
0
0
0
0
0
5,674
2,511
16,785
1,194
1,226
0
357
0
5,000
3,200
3,400
0
2,700
2,70003,4003,2005,000035701,2261,19416,7852,5115,6740000008,5468,546046404640004380
       Other Current Assets 
2,691
3,186
100
100
2,442
3,381
4,020
4,827
8,445
16,539
14,052
17,378
14,987
14,675
17,535
9,828
9,665
20,284
15,963
16,029
15,140
30,601
30,914
45,575
32,471
36,104
36,709
33,075
33,628
26,926
26,92633,62833,07536,70936,10432,47145,57530,91430,60115,14016,02915,96320,2849,6659,82817,53514,67514,98717,37814,05216,5398,4454,8274,0203,3812,4421001003,1862,691
   > Long-term Assets 
0
89,112
0
0
22,066
77,114
236,531
194,637
161,072
181,148
177,063
141,623
108,601
123,200
91,080
87,928
99,440
108,625
116,236
168,070
394,457
506,928
332,422
177,862
89,080
87,923
84,182
81,672
93,893
89,780
89,78093,89381,67284,18287,92389,080177,862332,422506,928394,457168,070116,236108,62599,44087,92891,080123,200108,601141,623177,063181,148161,072194,637236,53177,11422,0660089,1120
       Property Plant Equipment 
3,168
15,262
14,969
14,969
14,635
14,923
14,860
13,323
16,245
25,162
71,362
81,842
81,825
80,655
79,078
76,934
75,241
73,464
73,612
71,972
71,208
69,608
67,942
68,458
72,963
74,524
70,166
67,238
74,851
71,637
71,63774,85167,23870,16674,52472,96368,45867,94269,60871,20871,97273,61273,46475,24176,93479,07880,65581,82581,84271,36225,16216,24513,32314,86014,92314,63514,96914,96915,2623,168
       Long Term Investments 
0
73,080
25,875
25,875
4,975
61,250
219,406
178,703
142,173
147,881
97,554
55,832
23,534
39,886
9,684
7,229
20,341
32,699
38,885
92,522
319,472
425,449
250,268
94,220
0
0
0
0
7,905
0
07,905000094,220250,268425,449319,47292,52238,88532,69920,3417,2299,68439,88623,53455,83297,554147,881142,173178,703219,40661,2504,97525,87525,87573,0800
       Long-term Assets Other 
0
770
0
0
2,456
1,441
2,265
2,611
2,654
8,105
8,147
3,949
3,242
2,659
2,318
3,765
3,858
2,462
3,739
3,576
3,777
11,871
14,212
15,184
14,617
11,899
12,516
12,834
11,137
16,543
16,54311,13712,83412,51611,89914,61715,18414,21211,8713,7773,5763,7392,4623,8583,7652,3182,6593,2423,9498,1478,1052,6542,6112,2651,4412,456007700
> Total Liabilities 
4,009
16,548
18,055
18,055
17,172
20,925
74,925
81,783
83,296
115,139
159,948
162,431
164,781
158,341
150,554
145,170
187,756
453,749
442,505
437,110
437,689
441,871
402,931
408,014
416,303
417,812
442,638
118,909
118,446
122,963
122,963118,446118,909442,638417,812416,303408,014402,931441,871437,689437,110442,505453,749187,756145,170150,554158,341164,781162,431159,948115,13983,29681,78374,92520,92517,17218,05518,05516,5484,009
   > Total Current Liabilities 
3,481
9,106
10,786
10,786
10,154
14,164
17,167
31,008
31,617
32,786
43,244
46,549
46,685
45,344
47,635
58,464
105,413
71,699
54,610
51,412
54,251
378,245
341,240
348,160
360,670
363,922
391,080
69,357
71,180
77,982
77,98271,18069,357391,080363,922360,670348,160341,240378,24554,25151,41254,61071,699105,41358,46447,63545,34446,68546,54943,24432,78631,61731,00817,16714,16410,15410,78610,7869,1063,481
       Short-term Debt 
0
0
0
0
0
0
7,293
13,070
15,467
19,088
15,327
17,885
22,995
3,665
4,121
4,330
4,508
4,690
4,876
5,055
5,252
5,453
5,659
5,871
7,068
7,318
6,539
6,774
7,014
7,260
7,2607,0146,7746,5397,3187,0685,8715,6595,4535,2525,0554,8764,6904,5084,3304,1213,66522,99517,88515,32719,08815,46713,0707,293000000
       Accounts payable 
1,713
1,963
1,428
1,428
2,270
2,716
1,377
9,176
3,354
1,891
3,662
3,931
2,022
2,590
2,316
1,866
2,806
1,071
1,626
4,235
4,817
4,779
3,358
7,116
7,539
2,790
2,215
8,520
1,182
9,483
9,4831,1828,5202,2152,7907,5397,1163,3584,7794,8174,2351,6261,0712,8061,8662,3162,5902,0223,9313,6621,8913,3549,1761,3772,7162,2701,4281,4281,9631,713
       Other Current Liabilities 
1,768
7,143
886
886
7,884
11,448
7,356
13,117
15,605
19,468
16,434
20,020
26,478
20,350
33,048
36,268
50,460
84,910
63,306
65,858
78,840
95,424
41,596
44,749
55,524
63,761
92,569
53,218
62,984
61,239
61,23962,98453,21892,56963,76155,52444,74941,59695,42478,84065,85863,30684,91050,46036,26833,04820,35026,47820,02016,43419,46815,60513,1177,35611,4487,8848868867,1431,768
   > Long-term Liabilities 
0
7,442
0
0
7,018
6,761
57,758
50,775
51,679
82,353
116,704
115,882
118,096
112,997
102,919
86,706
82,343
382,050
387,895
385,698
383,438
63,626
61,691
59,854
55,633
53,890
51,558
49,552
47,266
44,981
44,98147,26649,55251,55853,89055,63359,85461,69163,626383,438385,698387,895382,05082,34386,706102,919112,997118,096115,882116,70482,35351,67950,77557,7586,7617,018007,4420
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-7,293
-13,070
-15,467
-19,088
56,085
53,026
46,920
68,865
67,793
66,612
65,407
64,175
62,916
61,396
59,990
53,101
57,086
55,525
54,978
53,032
50,546
48,751
46,887
44,981
44,98146,88748,75150,54653,03254,97855,52557,08653,10159,99061,39662,91664,17565,40766,61267,79368,86546,92053,02656,085-19,088-15,467-13,070-7,293000000
       Long-term Liabilities Other 
0
0
0
0
0
0
51,707
49,746
44,576
57,821
440
408
386
379
379
379
82,343
382,050
387,895
701
383,438
379
61,691
379
55,633
379
51,558
49,552
379
0
037949,55251,55837955,63337961,691379383,438701387,895382,05082,34337937937938640844057,82144,57649,74651,707000000
       Deferred Long Term Liability 
0
0
0
0
0
0
6,051
1,029
7,103
24,532
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000024,5327,1031,0296,051000000
> Total Stockholder Equity
32,674
254,519
-135,349
-135,349
193,137
465,796
539,028
490,272
461,179
546,845
516,648
475,173
438,197
394,890
545,311
502,167
882,550
1,150,531
1,105,353
1,072,705
1,012,277
962,291
917,927
884,448
811,303
1,042,430
966,706
1,186,825
1,118,331
1,030,954
1,030,9541,118,3311,186,825966,7061,042,430811,303884,448917,927962,2911,012,2771,072,7051,105,3531,150,531882,550502,167545,311394,890438,197475,173516,648546,845461,179490,272539,028465,796193,137-135,349-135,349254,51932,674
   Common Stock
170
2,688
400
400
2,768
1,201
1,252
1,259
1,266
1,273
1,279
1,283
1,286
1,288
1,382
1,385
1,524
1,531
1,537
1,541
1,545
1,548
1,554
1,558
1,564
1,686
1,694
1,700
1,707
1,711
1,7111,7071,7001,6941,6861,5641,5581,5541,5481,5451,5411,5371,5311,5241,3851,3821,2881,2861,2831,2791,2731,2661,2591,2521,2012,7684004002,688170
   Retained Earnings Total Equity00-897,385-1,080,7680-872,309-769,010-710,216-644,996-569,735-485,147-424,456-354,415-599,300-541,072-482,314-425,551-371,526-325,266-266,929-227,937-305,470-270,099-215,375000000
   Accumulated Other Comprehensive Income 
0
-373
0
0
-237
-368
-1,287
-1,493
-1,416
-649
332
879
562
350
835
551
11
-245
-232
-368
-521
-2,499
-9,251
-12,274
-11,853
-6,886
-2,517
-1,441
-651
643
643-651-1,441-2,517-6,886-11,853-12,274-9,251-2,499-521-368-232-24511551835350562879332-649-1,416-1,493-1,287-368-23700-3730
   Capital Surplus 
0
0
0
0
0
0
754,438
760,605
766,799
774,158
781,966
798,277
807,875
818,803
1,025,408
1,041,303
1,480,315
1,503,660
1,528,504
1,556,679
1,580,988
1,608,238
1,635,840
1,664,174
1,693,901
0
2,048,297
2,083,951
0
0
002,083,9512,048,29701,693,9011,664,1741,635,8401,608,2381,580,9881,556,6791,528,5041,503,6601,480,3151,041,3031,025,408818,803807,875798,277781,966774,158766,799760,605754,438000000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
355,716
-377
-377
359,416
656,660
754,438
760,605
766,799
774,158
781,966
798,277
807,875
818,803
1,025,408
1,041,303
1,480,315
1,503,660
1,528,504
1,556,679
1,580,988
1,608,238
1,635,840
1,664,174
1,693,901
2,018,617
2,048,297
2,083,951
2,114,013
2,144,811
2,144,8112,114,0132,083,9512,048,2972,018,6171,693,9011,664,1741,635,8401,608,2381,580,9881,556,6791,528,5041,503,6601,480,3151,041,3031,025,408818,803807,875798,277781,966774,158766,799760,605754,438656,660359,416-377-377355,7160



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue330,531
Cost of Revenue-16,726
Gross Profit313,805313,805
 
Operating Income (+$)
Gross Profit313,805
Operating Expense-510,504
Operating Income-196,699-196,699
 
Operating Expense (+$)
Research Development423,876
Selling General Administrative103,354
Selling And Marketing Expenses16,726
Operating Expense510,504543,956
 
Net Interest Income (+$)
Interest Income51,505
Interest Expense-0
Other Finance Cost-6,469
Net Interest Income45,036
 
Pretax Income (+$)
Operating Income-196,699
Net Interest Income45,036
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-145,194-248,204
EBIT - interestExpense = -196,699
-145,194
-145,224
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-196,699-145,194
Earnings Before Interest and Taxes (EBITDA)-179,973
 
After tax Income (+$)
Income Before Tax-145,194
Tax Provision--6
Net Income From Continuing Ops-124,429-145,188
Net Income-145,224
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses527,230
Total Other Income/Expenses Net51,505-45,036
 

Technical Analysis of Denali Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Denali Therapeutics Inc. The general trend of Denali Therapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Denali Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Denali Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 21.01 < 21.60 < 21.87.

The bearish price targets are: 19.24 > 18.93 > 16.11.

Tweet this
Denali Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Denali Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Denali Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Denali Therapeutics Inc. The current macd is 0.37850101.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Denali Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Denali Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Denali Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Denali Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartDenali Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Denali Therapeutics Inc. The current adx is 23.37.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Denali Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Denali Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Denali Therapeutics Inc. The current sar is 18.77.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Denali Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Denali Therapeutics Inc. The current rsi is 53.63. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Denali Therapeutics Inc Daily Relative Strength Index (RSI) ChartDenali Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Denali Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Denali Therapeutics Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Denali Therapeutics Inc Daily Stochastic Oscillator ChartDenali Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Denali Therapeutics Inc. The current cci is -1.00671141.

Denali Therapeutics Inc Daily Commodity Channel Index (CCI) ChartDenali Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Denali Therapeutics Inc. The current cmo is 6.29150748.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Denali Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartDenali Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Denali Therapeutics Inc. The current willr is -51.14503817.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Denali Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Denali Therapeutics Inc Daily Williams %R ChartDenali Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Denali Therapeutics Inc.

Denali Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Denali Therapeutics Inc. The current atr is 1.08461129.

Denali Therapeutics Inc Daily Average True Range (ATR) ChartDenali Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Denali Therapeutics Inc. The current obv is -23,912,248.

Denali Therapeutics Inc Daily On-Balance Volume (OBV) ChartDenali Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Denali Therapeutics Inc. The current mfi is 66.75.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Denali Therapeutics Inc Daily Money Flow Index (MFI) ChartDenali Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Denali Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Denali Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Denali Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.631
Ma 20Greater thanMa 5020.539
Ma 50Greater thanMa 10018.669
Ma 100Greater thanMa 20019.163
OpenGreater thanClose20.860
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Denali Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Denali Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Denali Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Denali Therapeutics Inc

I send you an email if I find something interesting about Denali Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Denali Therapeutics Inc.

Receive notifications about Denali Therapeutics Inc in your mailbox!